Rapid onset of efficacy in patients with psoriasis treated with ixekizumab: A pooled analysis of data from two phase 3 randomized clinical trials (UNCOVER-2 and UNCOVER-3)

被引：0
|
作者：
Leonardi, Craig [1 ]
Langley, Richard [2 ]
Blauvelt, Andrew [3 ]
Gordon, Kenneth [4 ]
Shrom, David [5 ]
Kerr, Lisa [5 ]
Stoyko, Ivaylo [5 ]
Reich, Kristian [6 ]
机构：
[1] St Louis Univ, Sch Med, St Louis, MO USA
[2] Dalhousie Univ, Halifax, NS, Canada
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Dermatologikum Hamburg, Hamburg, Germany
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
3100
引用
收藏
页码：AB70 / AB70
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) (vol 18, pg 273, 2017)
    Blauvelt, Andrew
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Puig, Luis
    Weisman, Jamie
    Dutronc, Yves
    Kerr, Lisa Farmer
    Ilo, Dapo
    Mallbris, Lotus
    Augustin, Matthias
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (03) : 457 - 457
  • [32] Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial
    Blauvelt, Andrew
    Lebwohl, Mark G.
    Mabuchi, Tomotaka
    Leung, Ann
    Garrelts, Alyssa
    Crane, Heidi
    ElMaraghy, Hany
    Patel, Himanshu
    Ridenour, Terri
    See, Kyoungah
    Gallo, Gaia
    Paul, Carle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (02) : 360 - 368
  • [33] Sustained high level of efficacy and favorable safety of ixekizumab in psoriasis: 4 years of follow-up from UNCOVER-3
    Lebwohl, Mark G.
    Gordon, Kenneth B.
    Paul, Carle
    Gallo, Gaia
    Zhang, Lu
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB128 - AB128
  • [34] Complete resolution of psoriasis is associated with greater improvements in itch and health-related quality of life: an analysis from UNCOVER-2, a phase 3 clinical trial of ixekizumab
    Griffiths, Christopher
    Blauvelt, Andrew
    Lebwohl, Mark
    Bleakman, Alison
    Nikai, Enkeleida
    Goldblum, Orin
    Reich, Kristian
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S17 - S17
  • [35] Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
    Egeberg, Alexander
    Kristensen, Lars Erik
    Vender, Ron
    Zaheri, Shirin
    EL Baou, Celine
    Gallo, Gaia
    Riedl, Elisabeth
    Schuster, Christopher
    ACTA DERMATO-VENEREOLOGICA, 2022, 102
  • [36] Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3
    van de Kerkhof, P.
    Guenther, L.
    Gottlieb, A. B.
    Sebastian, M.
    Wu, J. J.
    Foley, P.
    Morita, A.
    Goldblum, O.
    Zhang, L.
    Erickson, J.
    Ball, S.
    Rich, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 477 - 482
  • [37] Evaluation of inflammatory bowel disease in patients with plaque psoriasis studied in phase 3 trials of ixekizumab (UNCOVER trials): Adjudicated data from the induction period
    Langley, Richard
    Romiti, Ricardo
    Leonardi, Craig
    Reich, Kristian
    Warren, Richard
    Solotikin, Kathleen
    Xu, Wen
    Vangerow, Harald
    Hardin, Dana
    Bachelez, Herve
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB249 - AB249
  • [38] Evaluation of inflammatory bowel disease in patients with plaque psoriasis studied in phase 3 trials of ixekizumab (UNCOVER Trials): Adjudicated data from the induction period
    Langley, R.
    Romiti, R.
    Leonardi, C.
    Reich, K.
    Warren, R. B.
    Ohtsuki, M.
    Xu, W.
    Solotkin, K.
    Hardin, D.
    Bachelez, H.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S169 - S169
  • [39] Near or complete resolution of psoriasis is associated with greater improvements in itch and health-related quality of life: An analysis from UNCOVER-2, a phase 3 clinical trial of ixekizumab
    Burkhardt, N.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 41 - 41
  • [40] Time course of ixekizumab drug levels and the relationship at week 60 to efficacy in patients with moderate-to-severe plaque psoriasis (UNCOVER-3)
    Reich, K.
    Choi, S. L.
    Jackson, K.
    Mallbris, L.
    Blauvelt, A.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 : 39 - 39
12345